Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Robert Andrade sold 13,975 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.00, for a total transaction of $153,725.00. Following the transaction, the chief financial officer now owns 105,746 shares in the company, valued at $1,163,206. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Robert Andrade also recently made the following trade(s):

• On Thursday, January 4th, Robert Andrade sold 15,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.64, for a total transaction of $159,600.00.

Fennec Pharmaceuticals Stock Up 1.8 %

Fennec Pharmaceuticals stock opened at $11.09 on Thursday. The company’s fifty day simple moving average is $9.90 and its 200-day simple moving average is $9.00. Fennec Pharmaceuticals Inc has a 12 month low of $6.30 and a 12 month high of $11.92. The stock has a market cap of $299.74 million, a P/E ratio of -18.17 and a beta of 0.35.

Hedge Funds Weigh In On Fennec Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of FENC. UBS Group AG grew its holdings in shares of Fennec Pharmaceuticals by 4,742.2% during the 3rd quarter. UBS Group AG now owns 3,099 shares of the company’s stock valued at $26,000 after acquiring an additional 3,035 shares in the last quarter. Royal Bank of Canada lifted its stake in shares of Fennec Pharmaceuticals by 650.5% in the 2nd quarter. Royal Bank of Canada now owns 3,182 shares of the company’s stock valued at $28,000 after purchasing an additional 2,758 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Fennec Pharmaceuticals by 107.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after purchasing an additional 1,578 shares during the last quarter. BNP Paribas Arbitrage SNC lifted its stake in shares of Fennec Pharmaceuticals by 2,777.1% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 4,891 shares of the company’s stock valued at $43,000 after purchasing an additional 4,721 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Fennec Pharmaceuticals in the 3rd quarter valued at $50,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

FENC has been the topic of several research analyst reports. Wedbush reiterated an “outperform” rating and set a $16.00 price objective on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th. Craig Hallum lifted their price objective on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, March 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.